On November 3, 2025 Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, reported that the company will present an oral presentation on interim data from its Phase 1/2 multidose study of VGA039 for von Willebrand disease (VWD), along with additional posters on the program, at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, being held December 6-9, 2025, in Orlando, Fla. VGA039 is a first-in-class monoclonal antibody therapy with a novel mechanism of action that targets Protein S, thereby restoring balance to the blood clotting process.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details include:
Oral Presentation
Title: Subcutaneous, Every-Four-Week Maintenance Dosing of a Novel Protein S Antibody is Well-Tolerated and Substantially Reduces Bleeding Rates: Results from a Phase 1/2 Multidose Study of VGA039 in Patients with Von Willebrand Disease
Publication Number: 308
Oral Session: 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Insights into Diagnostics and Therapeutics of Bleeding in Inherited, Acquired Coagulopathies and BDUC
Presentation Date and Time: Saturday, December 6, 2025, 4:15 – 4:30 p.m. ET
Presenter: Allison Wheeler, M.D., MSCI
Poster Presentations
Title: The First Characterization of Disease Burden and Healthcare Resource Utilization for the Recent Definition of Severe Von Willebrand Disease Using a Large United States Real-World Dataset
Publication Number: 2611
Poster Session: 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I
Session Date and Time: Saturday, December 6, 2025, 5:30 – 7:30 p.m. ET
Presenter: Angela Weyand, M.D.
Title: VGA039 as a Protein S-Targeted Hemostatic Promoting Monoclonal Antibody, Promotes in-vitro Thrombin Generation in Plasma Samples from Subjects Across a Broad Range of Bleeding Disorders, Including Von Willebrand Disease, Hemophilia A, Hemophilia B and Hemophilia C
Publication Number: 1277
Poster Session: 321. Coagulation and Fibrinolysis: Basic and Translational: Poster I
Session Date and Time: Saturday, December 6, 2025, 5:30 – 7:30 p.m. ET
Presenter: Alina He, B.S.
Title: A Protein S-Targeting Monoclonal Antibody, VGA039, Improves Both Primary and Secondary Hemostatic Activity of Von Willebrand Disease Patient Blood in an ex vivo Vascularized Hemostasis-on-a-Chip
Publication Number: 3051
Poster Session: 321. Coagulation and Fibrinolysis: Basic and Translational: Poster II
Session Date and Time: Sunday, December 7, 2025, 6:00 – 8:00 p.m. ET
Presenter: Yumiko Sakurai, M.S.
About VGA039
VGA039 is a monoclonal antibody therapy with a novel mechanism of action that targets Protein S, thereby restoring balance to the blood clotting process. VGA039 has potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with VWD. As a subcutaneously self-administered antibody therapy with a convenient once monthly dosing regimen, VGA039 has the potential to dramatically reduce treatment burden for patients. VGA039 has received Fast Track and orphan drug designations from the United States Food and Drug Administration (FDA).
Interim positive data from a Phase 1 single ascending dose study of VGA039 in patients with VWD were previously reported at the Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) in December 2024. A Phase 1/2 multidose study is ongoing (NCT05776069), with an interim readout planned for presentation at the 2025 ASH (Free ASH Whitepaper) Annual Meeting. VGA039 has advanced into a Phase 3 study (NCT07115004), a global single arm cross-over study designed to investigate the safety and efficacy of subcutaneous administration of VGA039 as prophylaxis for bleeding in patients with every type of VWD. For additional information on our VIVID trials of VGA039, including how to enroll, please visit the website here.
About von Willebrand disease
Von Willebrand disease (VWD) is the most common inherited bleeding disorder in which the blood does not clot properly, caused by absent or defective von Willebrand factor (VWF). VWD patients may experience excessive bleeding with variability in severity and frequency, negatively impacting their daily lives. Current therapies for VWD prophylaxis include factor replacement therapies requiring multiple intravenous (IV) infusions every week. More than 130,000 people in the U.S. are diagnosed with VWD.
(Press release, Star Therapeutics, NOV 3, 2025, View Source [SID1234659280])